Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" id="d8565302e153">Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. </p>

Related collections

Author and article information

Contributors

Deepak L. Bhatt: (View ORCID Profile)

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: Massachusetts Medical Society

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date Created: January 27 2022

Publication date (Print): January 27 2022

Volume: 386

Issue: 4

Pages: 316-326

Affiliations

[1 ]From the Division of Rheumatology, Mayo Clinic, Rochester, MN (S.R.Y.); the Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston (D.L.B.); the Division of Rheumatology, University of Nebraska Medical Center, Omaha (T.R.M.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.G.K.); Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas (R.F.); Pfizer, Madrid (J.L.R.); Pfizer, New York (R.G....

Article

DOI: 10.1056/NEJMoa2109927

PubMed ID: 35081280

SO-VID: b2ef9ad7-4fba-4f71-8f59-77e98837759d

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 318

See all cited by

- Version 1